Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review
Following the approval of sintilimab for lung cancer immunotherapy in China in June 2021, real-world clinical practice has confirmed its efficacy and safety. Although there have been limited reports of immune-related myocarditis associated with sintilimab, no fatal cases have been reported to date....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1559173/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849702827292622848 |
|---|---|
| author | Haixia Yang Menglu Sun Xiaosha Zhou Yaxuan Han Shanshan Zhang Kelin Zhang Xiaoyan Zhang |
| author_facet | Haixia Yang Menglu Sun Xiaosha Zhou Yaxuan Han Shanshan Zhang Kelin Zhang Xiaoyan Zhang |
| author_sort | Haixia Yang |
| collection | DOAJ |
| description | Following the approval of sintilimab for lung cancer immunotherapy in China in June 2021, real-world clinical practice has confirmed its efficacy and safety. Although there have been limited reports of immune-related myocarditis associated with sintilimab, no fatal cases have been reported to date. This case report focuses on a 71-year-old male patient with lung squamous cell carcinoma who developed severe immune-mediated myocarditis after receiving sintilimab in combination with gemcitabine. The patient presented with immune myocarditis combined with acute myocardial infarction. Due to delayed diagnosis, the outcome was unfavorable. This case is a warning to clinicians for early identification, rapid diagnosis and standardized use of glucocorticoids and immunosuppressants in sindilizumab induced myocarditis and emphasize the importance of multidisciplinary collaboration in managing such rare but serious adverse events. |
| format | Article |
| id | doaj-art-e6b9f736a4314808b64237caa46cd70f |
| institution | DOAJ |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-e6b9f736a4314808b64237caa46cd70f2025-08-20T03:17:31ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-04-011210.3389/fcvm.2025.15591731559173Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature reviewHaixia Yang0Menglu Sun1Xiaosha Zhou2Yaxuan Han3Shanshan Zhang4Kelin Zhang5Xiaoyan Zhang6Department of Radiation Oncology, Xi'an Chest Hospital Affiliated to Northwest University, Xi'an, ChinaDepartment of Radiation Oncology, Xi'an Chest Hospital Affiliated to Northwest University, Xi'an, ChinaDepartment of Radiation Oncology, Xi'an Chest Hospital Affiliated to Northwest University, Xi'an, ChinaDepartment of Radiation Oncology, Xi'an Chest Hospital Affiliated to Northwest University, Xi'an, ChinaDepartment of Radiation Oncology, Xi'an Chest Hospital Affiliated to Northwest University, Xi'an, ChinaDepartment of Cardiovascular Medicine, Xi'an Chest Hospital Affiliated to Northwest University, Xi'an, ChinaDepartment of Radiation Oncology, Xi'an Chest Hospital Affiliated to Northwest University, Xi'an, ChinaFollowing the approval of sintilimab for lung cancer immunotherapy in China in June 2021, real-world clinical practice has confirmed its efficacy and safety. Although there have been limited reports of immune-related myocarditis associated with sintilimab, no fatal cases have been reported to date. This case report focuses on a 71-year-old male patient with lung squamous cell carcinoma who developed severe immune-mediated myocarditis after receiving sintilimab in combination with gemcitabine. The patient presented with immune myocarditis combined with acute myocardial infarction. Due to delayed diagnosis, the outcome was unfavorable. This case is a warning to clinicians for early identification, rapid diagnosis and standardized use of glucocorticoids and immunosuppressants in sindilizumab induced myocarditis and emphasize the importance of multidisciplinary collaboration in managing such rare but serious adverse events.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1559173/fulllung cancersintilimabimmune myocarditismultidisciplinary collaborationdelayed diagnosiscase report |
| spellingShingle | Haixia Yang Menglu Sun Xiaosha Zhou Yaxuan Han Shanshan Zhang Kelin Zhang Xiaoyan Zhang Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review Frontiers in Cardiovascular Medicine lung cancer sintilimab immune myocarditis multidisciplinary collaboration delayed diagnosis case report |
| title | Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review |
| title_full | Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review |
| title_fullStr | Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review |
| title_full_unstemmed | Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review |
| title_short | Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review |
| title_sort | severe immune mediated myocarditis caused by sintilimab combined with gemcitabine a case report and literature review |
| topic | lung cancer sintilimab immune myocarditis multidisciplinary collaboration delayed diagnosis case report |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1559173/full |
| work_keys_str_mv | AT haixiayang severeimmunemediatedmyocarditiscausedbysintilimabcombinedwithgemcitabineacasereportandliteraturereview AT menglusun severeimmunemediatedmyocarditiscausedbysintilimabcombinedwithgemcitabineacasereportandliteraturereview AT xiaoshazhou severeimmunemediatedmyocarditiscausedbysintilimabcombinedwithgemcitabineacasereportandliteraturereview AT yaxuanhan severeimmunemediatedmyocarditiscausedbysintilimabcombinedwithgemcitabineacasereportandliteraturereview AT shanshanzhang severeimmunemediatedmyocarditiscausedbysintilimabcombinedwithgemcitabineacasereportandliteraturereview AT kelinzhang severeimmunemediatedmyocarditiscausedbysintilimabcombinedwithgemcitabineacasereportandliteraturereview AT xiaoyanzhang severeimmunemediatedmyocarditiscausedbysintilimabcombinedwithgemcitabineacasereportandliteraturereview |